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Edited by Varda RotterAbstract Cks2 proteins are essential components of cyclin/cy-
clin-dependent kinase complexes and contribute to cell cycle con-
trol. We identify Cks2 as a transcriptional target downregulated
by the tumor suppressor p53. Cks2 expression was found to be
repressed by p53 both at the mRNA and the protein levels. p53
downregulates transcription from the Cks2 promoter in a dose-
dependent manner and in all cell types tested. This repression ap-
pears to be independent of p53 binding to the Cks2 promoter. In
contrast to p53, neither p63 nor p73 proteins can repress Cks2
transcription. Thus p53, rather than its homologues p63 and
p73, may contribute to control of the ﬁrst metaphase/anaphase
transition of mammalian meiosis by downregulation of Cks2
expression.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The cyclin-dependent kinase subunit (Cks) family is com-
posed of small proteins (9–18 kDa). They are essential compo-
nents of cyclin/cyclin-dependent kinase complexes and thereby
contribute to cell cycle control [1]. The ﬁrst member of this
family isolated was the product of suc1 (suppressor of cdc2
mutation), which is necessary for the function of cell cycle reg-
ulatory protein kinase p34cdc2 in ﬁssion yeast [2]. Homologues
of Suc1, named Cks, were identiﬁed since then in many species
and share extensive sequence conservation. Co-immunoprecip-
itation studies have shown tight binding of Cks proteins to mi-
totic cyclin-dependent kinases [3]. Mammalian cells express
two paralogs like the human Cks1 and Cks2 proteins sharing
81% identity in their amino acid sequence [1].
Cks2 may be able to compensate for some of the functions
lost when Cks1 is deleted in Cks1/ mice [4]. Cks2/ ani-
mals are found to be viable but sterile in both sexes. This ste-
rility was found to be due to an arrest of the germ cells at
metaphase I of meiosis. As all events of meiotic prophase I*Corresponding author. Fax: +49 341 9712209.
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arrest is most likely caused by an inability to enter anaphase
I of meiosis rather than a checkpoint-mediated metaphase I ar-
rest. However, overexpression of Cks1 as well as of Cks2 could
abrogate metaphase I arrest. Thus, incomplete development of
germ cells in Cks2-deﬁcient cells results from the absence of
Cks1 expression rather than from a germ cell speciﬁc function
of Cks2 [5].
A principal factor in regulation of growth arrest as well as
apoptosis is the tumor suppressor protein p53. The gene of
p53 is mutated in the majority of human tumors and acts by
engaging in complexes with other proteins or functions as a
transcription factor. p53 functions as a transactivator and
repressor. One prominent example of a transactivated target
gene is the cdk inhibitor p21WAF1/CIP1 [6]. Other target genes
such as several regulators of the G2/M checkpoint like cyclin
B, cdc25C and cdk1 are repressed by p53 [7–10]. Many inves-
tigations concentrated on solving the mechanism of the p53-
dependent repression without identifying one mechanism
which would yield a general explanation for the regulatory de-
tails. Most repressed genes do not have p53-consensus site in
their promoters. For the cdk1 and cdc25C promoters we and
others have shown that p53-dependent repression can be med-
iated through CCAAT-boxes [7,9,10]. Lo¨hr et al. implicated
induction of p21WAF1/CIP1 in the transcriptional downregula-
tion by p53 [11]. In contrast to common somatic tumors, p53
gene mutations with less than 3% occur seldom in germ cell tu-
mors. The high level of wild-type p53 found in these tumors
may contribute in part to the chemosensitivity of germ cell tu-
mors [12]. Recently, it has been shown that p53 may be in-
volved in homologous recombination and/or checkpoint
control by directly binding to DMC1 protein to repress geno-
mic instability in meiotic germ cells [13].With p63 and p73 two
genes coding for proteins homologous to p53 have been iden-
tiﬁed. The p53, p63 and p73 proteins share a similar basic do-
main structure and display substantial amino acid identity in
their DNA-binding domains. p63 and p73 proteins do not rep-
resent classical tumor suppressors as their genes are rarely
found mutated or deleted in tumors. Unlike p53-deﬁcient mice,
p63 and p73 knockouts do not show enhanced cancer suscep-
tibility but exhibit severe developmental abnormalities. How-
ever, some of the functions of p63 and p73 overlap with the
role of p53. For example, all three proteins can activate tran-
scription of several of the same genes such as p21WAF1/CIP1
and Bax [14,15].blished by Elsevier B.V. All rights reserved.
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2.1. Plasmids and cloning of the Cks2 promoter
The human wild-type Cks2 promoter fragment, containing 654
nucleotides upstream of the start codon, was obtained by PCR ampli-
ﬁcation with the primers Cks2_human_for, 5 0-GGG GTA CCC CCC
AGC CGA CCA CGA AGC CG-3 0, and Cks2_human_rev, 5 0-CAT
GCC ATG GTG CTG GCG CGC TGC AGA AAA TG-3 0 and
cloned (KpnI/NcoI) in pGL3-Basic (Promega). The resulting clone
was sequenced yielding identical nucleotide sequences which was sub-
mitted to the data base (GenBank Accession No. EF026653).
Human p53-expression plasmids, pCMV-p53wt and pCMV-
p53mut, were generously provided by Vogelstein [16]. The wild-type
and mutant expression constructs of p73a, p73b, TAp63a, TAp63c,
TA*p63a, TA*p63c, DNp63a and DNp63c have been described previ-
ously [17]. The plasmid YA13m29 expresses a dominant-negative mu-
tant of transcription factor subunit NF-YA and has been described
previously [18]. The control plasmid pRL-null (Promega) contains a
cDNA coding for Renilla luciferase.
2.2. Cell culture, transfections and luciferase assay
Parental HCT116 cells and HCT116 cells with targeted deletion in
both p53 alleles [19] as well as inducible cell line D.P53 A2 (DLD-1-
tet-oﬀ-p53) was generously provided by Vogelstein [20]. The latter cell
line is a derivative of the colorectal carcinoma cell line DLD-1, which
has endogenous mutant p53 alleles. Expression of wild-type p53 is reg-
ulated by a modiﬁed tetracycline (tet)-regulated gene expression system
(tet-oﬀ-system) [8,20,21].
HCT116, DLD-1, SaOS-2, HeLa, HS766T and C33A cells were cul-
tured and transiently transfected as described [8,22–24]. Unless other-
wise noted, transfections were carried out using 300 ng of Cks2
promoter construct and 25 ng of p53, p73 or p63 expression plasmids
and pRL-null control plasmid per assay. DNA amounts were held con-
stant using pUC19 plasmid. Luciferase activity was measured 24 h
after transfection. Fireﬂy luciferase was normalized to Renilla lucifer-
ase activity in order to compensate for variability in transfection eﬃ-
ciencies.
2.3. Western blotting and oligonucleotide microarray analysis
Frozen cell pellets were lysed in TRIZOL Reagent (Invitrogen) and
proteins were extracted as suggested by the manufacturer. Protein con-
centrations were determined with the Bio-Rad protein assay kit and
100 lg of total cell lysate per sample was separated in a 15% SDS–
polyacrylamide gel. Proteins were transferred onto a polyvinylidene
diﬂuoride transfer membrane (Hybond-P; Amersham Pharmacia Bio-
tech) and blocked with 5% BSA/TBS-Tween 20. Antibodies employed
were the anti-Cks2 mouse monoclonal antibody (1F7G5, 3 lg/ll,
Zymed), the anti-p53 mouse monoclonal antibody (DO-1, 1:2000,
Oncogene) and the anti-b-actin monoclonal antibody (AC-1, 1:2000,
Sigma). Goat-anti-mouse IgG conjugated with horseradish peroxidase
(Pierce) was used as a secondary antibody and chemiluminescent sig-
nals were detected by Supersignal West Dura Extended Duration
Chemiluminescent Substrate Kit (Pierce). Oligonucleotide microarray
analysis was performed as described previously [25].
2.4. RNA extraction and real-time RT-PCR analysis
Extraction of total RNA and real-time RT-PCR mRNA quantiﬁca-
tion with the LightCycler system (Roche) including calculations have
been described [8,9]. Primers were used at 1 lM with 3 mM MgCl2
and 50 ng of RNA template in the QuantiTect SYBR Green RT-
PCR system (Qiagen) according to the manufacturer’s instructions.
Each cycle of PCR included 15 s of denaturation at 94 C, 20 s of pri-
mer annealing at 62 C (Cks2) or 55 C (p53, p73, TAp63 and DNp63)
and 15 s of extension/synthesis at 72 C. At the end of the extension
steps at 72 C (Cks2) or 79 C (p53, p73, TAp63 and DNp63) ﬂuores-
cence of each sample was measured to allow quantiﬁcation of
the mRNA. Gene-speciﬁc primers used for RT-PCR: Cks2-hum-for,
5 0-CAT TAC ATG ATT CAT GAG CCA G-3 0; Cks2-hum-rev, 5 0-
GTT TCA GTA AAC TCA AAC AGG CAC-3 0; p53-hum-for,
5 0-ATG GAG GAG CCG CAG TCA GAT C-3 0; p53-hum-rev, 5 0-
CCA TTG TTC AAT ATC GTC CGG G-30; p73-hum-for, 5 0-AAG
ACA TGC CCC ATC CAG ATC-3 0; p73-hum-rev, 5 0-CAT GAA
GTT GTA CAG GAT GGT G-3 0; TAp63-hum-for, 5 0-ATG TCC
CAG AGC ACA CAG AC-3 0; TAp63-hum-rev, 5 0-CAC ATG GGGTCA CTC AGG TC-3 0; DNp63-hum-for, 5 0-CTG GAA AAC AAT
GCC CAG AC-3 0; DNp63-hum-rev, 5 0-GTG GAA TAC GTC CAG
GTG GC-3 0; GAPDH-hum-for, 5 0-GAC CCC TTC ATT GAC CTC
AAC-3 0; GAPDH-hum-rev, 5 0-CAC GAC GTA CTC AGC GCC-3 0.
These primer pairs result in PCR products of 314 bp (Cks2), 159 bp
(p53), 303 bp (p73), 206 bp (TAp63), 296 bp (DNp63) and 186 bp
(GAPDH). Quantitative analysis was performed employing GAPDH
as a standard and LightCycler analysis software as described [8]. The
mRNA levels of untreated cells were set at 100%.
2.5. Chromatin immunoprecipitation assays
ChIPs of Cks2 and p21WAF1/CIP1 promoters were carried out as de-
scribed [25]. Samples were analyzed after 35 PCR cycles with the fol-
lowing primers: ChIP-Cks2hum-for, 5 0-CGA CCG ACT ACG TCA
TCA CC-3 0 and ChIP-Cks2hum-rev, 5 0-CCT CGC AAA GTC CGC
TTC C-3 0 (GenBank Accession No. EF026653). Primers for ampliﬁca-
tion of the human p21WAF1/CIP1 promoter fragment have been de-
scribed [25].3. Results and discussion
3.1. Expression of Cks2 mRNA is downregulated after increased
p53 expression
The human colorectal adenocarcinoma cell line DLD-1 is
negative for functional p53 protein. We employed a stably
transfected DLD-1 cell line which allows for tet-oﬀ-regulated
expression of wild-type p53 [8,20]. In control experiments we
had conﬁrmed that after tet-oﬀ induction for 9 h expression
of p53 mRNA and protein increases [8]. To search for hitherto
unidentiﬁed p53 target genes, we had performed a DNA
microarray hybridization experiment using RNA from these
DLD-1-tet-oﬀ-p53 cells without and 9 h after induction of
p53 expression [25]. We found Cks2 mRNA to be downregu-
lated 9.7-fold when wild-type p53 was overexpressed relative
to the uninduced state. As controls and consistent with previ-
ous observations mRNA levels for known p53 target genes like
p21WAF1/CIP1 and mdm2 were found to be upregulated and pre-
viously described targets like cyclin A, Cyclin B, cdk1 and
cdc25C were downregulated [25]. Furthermore, under the
experimental conditions employed changes in expression of
p53 target genes precede the changes due to impending apop-
tosis [17]. Following the microarray analysis as an indicator,
we conﬁrmed the p53-dependent decrease of the Cks2 mRNA
levels by real-time RT-PCR quantiﬁcation in two independent
experiments yielding an average of 10.1-fold downregulation
of Cks2 mRNA.
3.2. p53 downregulates transcription from the Cks2 promoter in
a dose-dependent manner and in diﬀerent cell types
In order to elucidate whether this decrease in Cks2 mRNA is
dependent on p53 as a regulator of transcription, we examined
the regulation of the Cks2 promoter. We ampliﬁed human
DNA upstream of the Cks2 coding region and cloned a
645 bp promoter fragment into a ﬁreﬂy luciferase-expressing
reporter plasmid (Cks2-Luci). Cks2-Luci together with expres-
sion constructs for wild-type or mutant p53 was cotransfected
in p53-negative SaOS-2 cells. Increasing amounts of wild-type
p53 led to a downregulation of the Cks2 reporter. In contrast,
the expression of a DNA-binding deﬁcient mutant of p53 at
the highest concentration had only a minor eﬀect on the
Cks2 reporter (Fig. 1A). In addition, similar experiments were
performed in diﬀerent cell lines including human cervical car-
cinoma cells HeLa and C33A, human colon carcinoma cells
_+ p53wt induction
Cks2
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Fig. 2. Western blot analysis of Cks2 expression after induction of
p53wt. DLD-1-tet-oﬀ-p53 cells without () and with (+) induction of
wild-type p53 expression for 9 h. Total cell lysate was prepared and
100 lg of protein was used for each lane. Samples were analyzed with
antibodies directed against human Cks2, p53 and b-actin.
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Fig. 1. p53 downregulates transcription from Cks2 promoter in a
dose-dependent manner. Either a plasmid coding for wild-type p53 or
a DNA-binding mutant of p53 was cotransfected along with the Cks2
promoter reporter in transient cotransfection assays. All experiments
were standardized to Renilla luciferase activity expressed from
cotransfected pRL-null vector. Experiments were carried out in
triplicate with standard deviations indicated. (A) The Cks2-Luci
construct carrying the human Cks2 promoter was cotransfected in
SaOS-2 cells with p53mut or increasing amounts of p53wt. The total
amount of DNA transfected was held constant by adding pUC19.
Cotransfection with pUC19 vector exclusively, served as a control and
set to 100%. (B) Diﬀerent cell lines were transfected with the Cks2
promoter reporter together with wild-type or mutant p53-expressing
plasmids. Maximum expression for each cell line was adjusted to 100%.
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Wild-type p53 downregulates transcription from the Cks2 pro-
moter in all cell systems (Fig. 1B).
3.3. Cks2 protein levels are also reduced after p53 induction
Lysates from DLD-1-tet-oﬀ-p53 cells before and after wild-
type p53 expression were prepared and Cks2 protein levels
were compared. Western blot analysis shows a moderate
reduction of Cks2 protein expression already 9 h after p53
induction (Fig. 2). This slight eﬀect is dependent on the lag
phase after mRNA decrease and stability of the Cks2 protein
and was consistently detected in several independent experi-
ments. Cks2 protein levels may further decrease with longer
periods of p53 induction. However, we had observed earlier
that after induction of p53 for more than 9 h a signiﬁcant num-
ber of cells have been become apoptotic [17].
3.4. Expression of p73 or p63 proteins does not alter
transcription from the Cks2 promoter
To test Cks2 promoter responsiveness to several p63 and p73
splice variants we employed plasmids coding for wild-type
TAp63a, TAp63c, TA*p63a, TA*p63c, DNp63a, DNp63c,p73a and p73b. Neither p73a or p73b nor any of the p63 splice
variants tested were able to change transcription from the
Cks2 promoter like p53 when compared to their DNA-binding
deﬁcient and transcriptionally inactive mutant forms (Fig. 3A).
Since cotransfections with p63 and p73 variants did not yield a
change in expression from the Cks2 promoter, we made sure in
control experiments that transient transfection of SaOS-2 cells
indeed lead to expression of each p63 and p73 splice variant
mRNA from the transfected plasmids (Fig. 3B). After real-
time RT-PCR samples were analyzed on agarose gels yielding
a strong induction of p53-family members in transfected cells.
No speciﬁc PCR product was detected in non-transfected con-
trol cells which therefore appeared negative for p53, p63 and
p73 mRNA. As another control, GAPDH mRNA levels re-
mained constant giving a quality control for the RNA prepa-
rations (Fig. 3B). Moreover, we had found p73a, p73b,
TAp63c and TA*p63c able to activate transcription from a
p21WAF1/CIP1 reporter [9,17]. This conﬁrms them to be trans-
criptionally active but unable to alter expression from the
Cks2 promoter. Inability of the other p63-splice variants to re-
press the Cks2 promoter may be due to absence of the transac-
tivation domain (DNp63a,DNp63c) or to deﬁciency in
transcriptional activity by an inhibitory function of the SAM
domain (TAp63a,TA*p63a) as described for p73 [26].
3.5. Repression of Cks2 transcription appears to be independent
of p53 binding to the Cks2 promoter
Transcriptional activation by p53 is generally associated
with p53 binding to the regulated promoter. The classical
p53-binding site exists of two palindrome pentamers, PuPu-
PuC(A/T)(T/A)GPyPyPy, separated by 0–13 bp [27]. In case
of transcriptional repression, direct binding of p53 to a consen-
sus site in the downregulated promoter usually is not detected.
Since human as well as mouse Cks2-promoter reporter-con-
structs were repressed in transient transfection assays by
wild-type p53 (data not shown) we performed an in silico anal-
ysis of human and mouse Cks2 promoter sequences (Fig. 4).
This comparison revealed that neither a classical p53-consen-
sus element nor alternative p53-binding sites were conserved
between the two species [28–31]. Furthermore, we searched
for other known consensus sites to be conserved in both pro-
moters. However, in these short promoter sequences we only
found three conserved CCAAT-boxes potentially binding the
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Fig. 3. Neither p63 nor p73 can downregulate Cks2 expression. (A) Luciferase reporter construct Cks2-Luci and expression plasmids coding for wild-
type and mutant protein of nine diﬀerent p53-family members (p53,p73a,p73b,TAp63a,TAp63c,TA*p63a,TA*p63c,DNp63a,DNp63c) were
transiently cotransfected in SaOS-2 cells. Experimental details were the same as in Fig. 1. (B) As controls Saos-2 cells were transiently cotransfected in
order to test for mRNA expression from plasmids coding for p53-family members. Total RNA was prepared 24 h after transfection, ampliﬁed by
real-time RT-PCR and visualized on agarose gels. GAPDH expression was tested as RNA preparation quality control. Expected product sizes were:
p53, 159 bp; p73, 303 bp; TAp63, 206 bp; DNp63, 296 bp; GAPDH, 186 bp. Control lanes C resulted from non-transfected cells. Marker lane is
denoted as M.
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tion (Fig. 4).
Although we did not ﬁnd a p53-consensus site in the Cks2
promoter, we test for direct or indirect binding of p53 to the
Cks2 promoter by chromatin immunoprecipitation assays
(ChIPs) using DLD-1-tet-oﬀ-p53 cells before (control) and
after selective induction of wild-type p53. With an antibody di-
rected against p53, no Cks2 promoter DNA could be co-pre-
cipitated and subsequently PCR-ampliﬁed (Fig. 5). Binding
of p53 to the p21WAF1/CIP1 promoter served as a positive con-
trol. Taken together, sequence and ChIP analyses indicate that
p53 does not bind to the Cks2 promoter as also observed with
other genes repressed by p53 [25].
3.6. NF-Y is not responsible for Cks2 promoter activity and does
not inﬂuence p53-dependent repression of Cks2
NF-Y is a transcriptional activator binding to CCAAT-
boxes and has been implicated in p53-dependent repression[7,9,10,32]. The human Cks2 promoter contains three
CCAAT-boxes (Fig. 4) and we tested the impact of NF-Y
on Cks2 regulation by employing YA13m29, a dominant-neg-
ative mutant of NF-Y subunit NF-YA [18]. Even the highest
amount of YA13m29 does not signiﬁcantly reduce Cks2 pro-
moter activity (Fig. 6). In control experiments we had con-
ﬁrmed that after YA13m29 expression human cyclin B2 and
cdc25C promoter activity decreases [22,24]. In the presence
of YA13m29 p53 is still able to repress Cks2 transcription
(Fig. 6). Thus, the experiments exclude NF-Y as responsible
for Cks2 promoter activation and as being a mediator in
p53-dependent repression of Cks2.
In summary, we identiﬁed with Cks2 a transcriptional
target downregulated by p53 that contributes to control of
the ﬁrst metaphase/anaphase transition of mammalian
meiosis. We found that p53 downregulates Cks2 expression
both at the transcriptional and the protein levels. This
repression is mediated obviously neither through direct nor
Fig. 4. Comparison of nucleotide sequences from human and mouse Cks2 promoters. Numbering is relative to the translation start codons. Identical
homologous nucleotides are indicated by vertical lines. CCAAT-boxes conserved in both sequences are boxed.
1170 K. Rother et al. / FEBS Letters 581 (2007) 1166–1172through indirect binding of p53 to the Cks2 promoter. In
contrast to p53, the related proteins p63 and p73 cannot
repress Cks2 transcription. Thus p53, rather than itshomologues p63 and p73, may contribute to controlling
transition of metaphase I to anaphase I in mammalian
meiosis.
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